Immune DIREcted and Cancer-selective immunoTherapy

Project Information

I-DireCT

Grant agreement ID: 813871

DOI 10.3030/813871

Project closed

EC signature date 21 August 2018

Start date 1 January 2019

End date 30 September 2023

Funded under

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Total cost € 2 532 975,22

EU contribution € 2 532 975,22

Coordinated by

ACADEMISCH ZIEKENHUIS GRONINGEN
Netherlands

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Documents, reports (11)

Frontiers in Immunology EBook
List of PhDs theses
Presentations at Antibody engineering workshops 2

Special IDireCT sessions at international conferences workshops

Presentations at Antibody engineering workshops

Special IDireCT sessions at international conferences workshops

Characterization of new tumour-selective TNFR family-targeted drugs

Characterization of new tumourselective TNFR familytargeted drugs

List of publications I-DireCT

List of publications of all IDireCT members

Update 4 online knowledge bases
Update 2 online knowledge bases
Update 1 online knowledge bases
Identification and pre-clinical validation of tumour-targeted checkpoint drugs

Identification and preclinical validation of tumourtargeted checkpoint drugs

Update 3 online knowledge bases

Other (3)

Report on kick-off meeting
Press event
I-DireCT summer school

Websites, patent fillings, videos etc. (1)

Website

I-DireCT public website

Publications

Peer reviewed articles (20)

DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity

Author(s): Ewa Cendrowicz; Lisa Jacob; Shirley Greenwald; Ami Tamir; Iris Pecker; Rinat Tabakman; Lucy Ghantous; Liat Tamir; Roy Kahn; Jasmine Avichzer; Alexandra Aronin; Shira Amsili; Elina Zorde-Khvalevsky; Yosi Gozlan; Martijn Vlaming; Gerwin Huls; Tom van Meerten; Michal Elhalel Dranitzki; Adam Foley-Comer; Yaron Pereg; Amnon Peled; Ayelet Chajut; Edwin Bremer
Published in: VOLUME=41;ISSN=0392-9078;TITLE=Journal of experimental & clinical cancer research, Issue 5, 2022, ISSN 1756-9966
Publisher: BioMed Central Ltd
DOI: 10.1186/s13046-022-02256-x

CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties

Author(s): Martijn Vlaming, Vrouyr Bilemjian, Jimena Álvarez Freile, Harm Jan Lourens, Nienke van Rooij, Gerwin Huls, Tom van Meerten, Marco de Bruyn, Edwin Bremer
Published in: Scientific Reports, 2021, ISSN 2045-2322
Publisher: Nature Publishing Group
DOI: 10.1038/s41598-021-00007-0

Receptor Oligomerization and Its Relevance for Signaling by Receptors of the Tumor Necrosis Factor Receptor Superfamily

Author(s): Kirstin Kucka, Harald Wajant
Published in: Frontiers in Cell and Developmental Biology, Issue 8, 2021, ISSN 2296-634X
Publisher: Frontiers Media S.A.
DOI: 10.3389/fcell.2020.615141

Whispering Gallery Modes-based biosensors for real-time monitoring and binding characterization of antibody-based cancer immunotherapeutics

Author(s): Jimena Álvarez Freile; Ghizlane Choukrani; Kerstin Zimmermann; Edwin Bremer; Lars Dähne
Published in: Sensors and actuators b-Chemical, 346:130512. Elsevier Science, Issue 4, 2021, ISSN 0925-4005
Publisher: Elsevier BV
DOI: 10.1016/j.snb.2021.130512

Development of vaterite particles for therapeutic protein drug delivery and pH-sensitive release mimicking the tumor microenvironment.

Author(s): Ghizlane Choukrani, Jimena Álvarez Freile, Wei Wan, Gabriella Egri, Natasha Ustyanovska Avtenyuk (ESR2, UMCG/SURF), Valerie Wiersma, Edwin Bremer, Lars Dähne
Published in: Particle, 2021, ISSN 2571-712X
Publisher: MDPI AG
DOI: 10.1002/ppsc.202100012

Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment

Author(s): Vinicio Melo, Edwin Bremer, John D. Martin
Published in: Frontiers in immunology, 2022, ISSN 1664-3224
Publisher: Frontiers Media S.A.
DOI: 10.3389/fcell.2022.908389

CD24 is a potential immunotherapeutic target for Mantle Cell Lymphoma

Author(s): Jimena Álvarez Freile, Natasha Ustyanovska Avtenyuk, Macarena González Corrales, Harm Jan Lourens, Gerwin Huls, Tom van Meerten, Ewa Cendrowicz, and Edwin Bremer
Published in: Biomedicines, 2022, ISSN 2227-9059
Publisher: MDPI
DOI: 10.3390/biomedicines10051175

Membrane lymphotoxin-α2β is a novel tumor necrosis factor (TNF) receptor 2 (TNFR2) agonist

Author(s): Kucka, Kirstin; Lang, Isabell; Zhang, Tengyu; Siegmund, Daniela; Medler, Juliane; Wajant, Harald
Published in: Cell Death and Disease, Vol 12, Iss 4, Pp 1-9 (2021), Issue 6, 2021, ISSN 2041-4889
Publisher: Nature Publishing Group
DOI: 10.1038/s41419-021-03633-8

The Novel Immune Checkpoint GPR56 Is Expressed on Tumor-Infiltrating Lymphocytes and Selectively Upregulated upon TCR Signaling

Author(s): Vrouyr Bilemjian; Martijn R. Vlaming; Jimena Álvarez Freile; Gerwin Huls; Marco De Bruyn; Edwin Bremer
Published in: Cancer (Basel), Issue 9, 2023, ISSN 2072-6694
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers14133164

CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism

Author(s): Juliane Medler, Kirstin Kucka, Vinicio Melo, Tengyu Zhang, Stefan von Rotenhan, Jakob Ulrich, Edwin Bremer, Michael Hudecek, Andreas Beilhack, and Harald Wajant
Published in: Theranostics, 2022, ISSN 1838-7640
Publisher: Ivyspring International Publisher
DOI: 10.7150/thno.66119

Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism.

Author(s): Ahmed Aido; Olena Zaitseva; Harald Wajant; Matej Buzgo; Aiva Simaite
Published in: Pharmaceutics, Issue 6, 2021, ISSN 1999-4923
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics13071072

Galectin-9 has non-apoptotic cytotoxic activity towards Acute Myeloid Leukemia independent of cytarabine resistance.

Author(s): Ghizlane Choukrani, Nienke Visser, Natasha Ustyanovska Avtenyuk, Mirjam Olthuis, Glenn Marsman, Emanuele Ammatuna, Harm Jan Lourens, Toshiro Niki, Gerwin Huls, Edwin Bremer and Valerie R. Wiersma.
Published in: Cell Death Discovery, 2023, ISSN 2058-7716
Publisher: Nature Publishing Group
DOI: 10.1038/s41420-023-01515-w

Facing the Challenges of Pharmaceutical Research Using Whispering Gallery Modes-Based Biosensors

Author(s): Lars Dähne
Published in: American Journal of Biomedical Science & Research, Issue 8/2, 2020, Page(s) 161-162, ISSN 2642-1747
Publisher: Biomedgrid
DOI: 10.34297/ajbsr.2020.08.001259

Galectin-9 Triggers Neutrophil-Mediated Anticancer Immunity

Author(s): Natasha Ustyanovska Avtenyuk; Ghizlane Choukrani; Emanuele Ammatuna; Toshiro Niki; Ewa Cendrowicz; Harm Jan Lourens; Gerwin Huls; Valerie R. Wiersma; Edwin Bremer
Published in: Biomedicines, Vol 10, Iss 66, p 66 (2022), Issue 4, 2021, ISSN 2227-9059
Publisher: MDPI
DOI: 10.3390/biomedicines10010066

Antibody-based soluble and membrane-bound TWEAK mimicking agonists with FcγR-independent activity.

Author(s): Zaitseva O, Hoffmann A, Löst M, Anany MA, Zhang T, Kucka K, Wiegering A, Otto C, Wajant H.
Published in: Frontiers in immunology, 2023, ISSN 1664-3224
Publisher: Frontiers Media S.A.
DOI: 10.3389/fimmu.2023.1194610

The Neutrophil: The Underdog That Packs a Punch in the Fight against Cancer

Author(s): Natasha Ustyanovska Avtenyuk, Nienke Visser, Edwin Bremer, Valerie R. Wiersma
Published in: International Journal of Molecular Sciences, Issue 21/21, 2020, Page(s) 7820, ISSN 1422-0067
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/ijms21217820

Tumor infiltrating CD8/CD103/TIM-3-expressing lymphocytes in epithelial ovarian cancer co-express CXCL13 and associate with improved survival

Author(s): Martijn Vlaming, Vrouyr Bilemjian, Jimena Álvarez Freile, Vinicio Melo, Annechien Plat, Gerwin Huls, Hans W. Nijman, Marco de Bruyn, Edwin Bremer
Published in: Front. Immunol., 2022, ISSN 1664-3224
Publisher: Frontiers Media S.A
DOI: 10.3389/fimmu.2022.1031746

Using Nanomedicine to Drive Advances in Cancer Immunotherapy: A Mini Review.

Author(s): Choukrani G, Freile JA, Bremer E, Daehne L
Published in: American Journal of Biomedical Science & Research, 2020, ISSN 2642-1747
Publisher: Biomedgrid
DOI: 10.34297/ajbsr.2020.08.001248

EGFR-selective activation of CD27 co-stimulatory signaling by a bispecific antibody enhances anti-tumor activity of T cells

Author(s): Vinicio Melo, Levi Collin Nelemans, Martijn Vlaming, Harm Jan Lourens, Valerie R. Wiersma, Vrouyr Bilemjian, Gerwin Huls, Marco de Bruyn, and Edwin Bremer
Published in: Frontiers in immunology, 2023, ISSN 1664-3224
Publisher: Frontiers Media S.A.
DOI: 10.3389/fimmu.2023.1191866

A luminescence-based method to assess antigen presentation and antigen-specific T cell responses for in vitro screening of immunomodulatory checkpoints and therapeutics

Author(s): Jimena Álvarez Freile; Yuzhu Qi; Lisa Jacob; Maria Franceskin Lobo; Harm Jan Lourens; Gerwin Huls; Edwin Bremer
Published in: Crossref, Issue 2, 2023, ISSN 1664-3224
Publisher: Frontiers Media S.A
DOI: 10.3389/fimmu.2023.1233113

Thesis and dissertations (1)

Advancing Cancer Immunotherapy with Nanomedicine

Author(s): Ghizlane Choukrani
Published in: 2023
Publisher: University of Groningen
DOI: 10.33612/diss.660794643